However, semaglutide remains a highly effective treatment for weight loss, especially for individuals who want a well-established medication with a proven track record
Its not a magic bullet, but it may offer layered support for those seeking consistency, resilience, and accelerated return-to-training timelines
Larger Phase 3 trials are required before regulatory approval can be sought, and results in real-world clinical practice may differ from those observed under trial conditions
GLP-1 receptor agonists in heart failure GLP-1 receptor agonists have demonstrated favorable cardiovascular effects in patients with T2DM and obesity as meta-analyses suggest a reduction in hospitalization for incident or new-onset HF of approximately 18%, alongside reductions in major adverse cardiovascular events [6, 14, 15]
Start on day one of GLP-1 therapy
21 (4): p